Aortic stent Graft innovator Endologix, Inc., tells us it has completed enrollment in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study. The 75-patient study is evaluating the safety and effectiveness of the Alto Abdominal Stent Graft System for the repair of infrarenal abdominal aortic aneurysms (AAAs).
Endologix develops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA).
Alto is Endologix’s latest-generation Polymer EVAR system. It aims to expands patient applicability by moving the polymer sealing ring near the proximal edge of the graft. The new device was designed based upon physician feedback and the positive clinical results from the Ovation platform that has been extensively studied in over 1,300 patients from five prospective studies over the past seven years.
The Company plans to file regulatory submissions in the third quarter of 2018 and anticipates potential approval of the Alto device in both the U.S. and European markets in 2019.
The study’s principal investigator, Dr. Sean Lyden, Chairman of the Department of Vascular Surgery at Cleveland Clinic, commented, “We are pleased to complete enrollment of the ELEVATE IDE Trial and look forward to evaluating the clinical results later this year. The Alto device incorporates several design enhancements that are intended to simplify the procedure and enable the system to treat a wider range of AAA anatomies than Ovation iX.”
John McDermott, Chief Executive Officer of Endologix, Inc., said, “Enrollment of the ELEVATE IDE Trial is an important step in advancing our portfolio of innovative technologies for aortic patients. I would like to thank the physicians who have provided input into the Alto device, as well as the clinical investigators and their teams for participating in the study. We look forward to working with the global regulatory agencies and making the Alto device available for physicians and their patients as soon as possible.”
Source: Endologix, Inc.